Bristol Myers Squibb Company $BMY Shares Acquired by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer B.V. increased its Bristol Myers Squibb stake by 4.7% in the third quarter, acquiring 27,824 shares for a total holding of 622,760 shares valued at approximately $38.9 million. Institutional investors and hedge funds collectively own 76.41% of BMY.
• BMY shares opened at $59.51, below their 50-day moving average of $64.27, while the company reported quarterly revenue of $12.97 billion and earnings of $2.04 per share, exceeding analyst estimates.
• Bristol Myers Squibb declared a quarterly dividend of $0.63 per share, equivalent to a 4.2% annualized yield. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $66.72.

Mn Services Vermogensbeheer B.V. raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 622,760 shares of the biopharmaceutical company's stock after purchasing an additional 27,824 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Bristol Myers Squibb were worth $38,860,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb during the second quarter worth about $27,000. Addison Advisors LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $32,000. Bayban bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Groupe la Francaise raised its holdings in Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 501 shares during the last quarter. Finally, Kilter Group LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $35,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Down 0.3%

BMY stock opened at $59.51 on Friday. The stock's 50 day simple moving average is $64.27 and its 200 day simple moving average is $60.28. The company has a market cap of $121.57 billion, a P/E ratio of 13.11, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 earnings per share. The company's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BMY shares. Piper Sandler reiterated an "overweight" rating and set a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a research report on Wednesday, September 16th. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $63.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, September 23rd. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Finally, Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of "Moderate Buy" and a consensus price target of $66.72.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: ZENBEXUS delivered a significant Phase 3 result. Bristol Myers said the iberdomide combination with daratumumab and dexamethasone produced superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma, cutting the risk of disease progression or death by 51%. The result strengthens the company’s pipeline and could support broader use of the therapy. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: ZENBEXUS met the primary progression-free-survival endpoint in a pivotal trial. The update adds evidence behind the drug’s commercial potential following an earlier approval tied to achievement of another endpoint in the same study. BMS Zenbexus Meets PFS Endpoint
• Positive Sentiment: Analysts expect another earnings beat. Coverage points to Bristol Myers’ history of exceeding estimates and a favorable combination of earnings expectations and estimate revisions, though this is a forecast rather than a reported result. Will Bristol Myers Beat Estimates Again
• Positive Sentiment: Growth assets and income appeal remain part of the bullish case. Coverage highlights Reblozyl’s sales growth and potential new indications, a Camzyos label expansion, and BMY’s relatively attractive value and dividend profile as offsets to declining legacy-drug sales.
• Neutral Sentiment: ZENBEXUS’ ultimate impact will depend on regulatory steps, commercial uptake and competitive positioning in multiple myeloma.
• Negative Sentiment: Cantor Fitzgerald lowered its BMY price target from $59 to $53 and maintained a Neutral rating. The reduced target signals limited near-term upside in the firm’s view and is the clearest negative analyst catalyst in the latest coverage.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.05% of the company's stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.